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Purpose: The objectives of this study were to determine whether high-glucose-induced upregulation of heparanase
(HPSE) expression and differential heparanase expression in human retinal vascular endothelial cells (HRECs) can alter
HREC migration and proliferation. We also aimed to determine whether HREC migration and proliferation correlate with
the levels of protein kinase B (Akt) and extracellular-signal-regulated kinase (ERK) phosphorylation and activation.
Methods: HRECs were treated with either 5 mM glucose (Glu5) or high (30 mM) glucose (Glu30) for 48 h. Untransfected
HRECs  were  grown  in  human  endothelial  serum-free  medium  (HE-SFM)  in  the  presence  of  5  mM  glucose  and
supplemented with 30 mM mannitol for 48 h as an osmotic control (mannitol). HRECs were also infected with a heparanase
small interfering RNA recombinant lentiviral vector (HPSE-LV) or a control vector (Con-LV) at a multiplicity of infection
(MOI) of 60 for three days. Then the con-LV and HPSE-LV-infected cells were treated with 30 mM glucose for 48 h
(Con-LV-Glu30 and HSPE-LV-Glu30, respectively). The expression levels of heparanase mRNA and protein and HREC
proliferation and migration were examined using quantitative real-time polymerase chain reaction (qRT–PCR), western
blot analysis, 3-(4,5-dimethylthiahiazol-2-y1)-2,5-diphenyltetrazolium bromide assay, bromodeoxyuridine histochemical
staining, and the Boyden chamber assay. The expression level of paxillin was examined using immunofluorescent staining.
Akt and ERK phosphorylation was evaluated using western blot analysis.
Results: We successfully transfected the HPSE RNAi lentiviral vector into HRECs and demonstrated that it can suppress
the expression of the heparanase gene in these cells. Western blot and qRT–PCR analyses showed that HRECs treated
with a high concentration of glucose exhibited increased heparanase protein and mRNA levels, while the levels were
decreased in HRECs that had been infected with HPSE-LV before treatment with high glucose (HPSE-LV-Glu30; p<0.05).
The observed increase or decrease in the levels of heparanase correlated with increased or decreased HREC migration
and proliferation, respectively (p<0.05). HREC proliferation and migration were found to correlate with Akt and ERK
phosphorylation levels (p<0.5).
Conclusions: Our results indicate that heparanase plays a significant role in mediating retinal vascular endothelial cell
proliferation and migration after the HRECs are exposed to high levels of glucose. Signaling inducing heparanase-
stimulated  HREC  proliferation  and  migration  appears  to  be  related  to  the  activation  of  Akt  and  ERK  via  their
phosphorylation.
Diabetes  is  the  primary  chronic  systemic  disease
responsible for visual loss [1]. Diabetic retinopathy (DR) is
the  leading  cause  of  preventable  blindness  in  adults
worldwide [2]. Developing countries with rapidly evolving
economies face the challenge of a DR epidemic [3,4].
Angiopathy,  a  complication  of  diabetes  mellitus,  is
characterized by microvascular pathology in the retina and
renal glomerulus. Abnormal angiogenesis-induced vascular
leakage, endothelial cell damage [5,6] and severely impaired
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retinal function are the consequences of retinal hypoxia and
ischemia.  The  endothelial  cells  (ECs)  that  line  the  blood
vessels appear to be the initial targets of the vascular damage
due  to  hyperglycemia.  Furthermore,  changes  due  to
hyperglycemia  can  cause  vascular  remodeling  [7].  These
abnormalities result in vasoconstriction, hypertension, tissue
ischemia, and eventually infarction and an increase in vascular
permeability [8].
Heparan sulfate (HS) is a glycosaminoglycan associated
with  the  cell  membrane,  basement  membrane,  and
extracellular matrix (ECM) [9]. The depletion of HS and/or
alteration in its metabolism is considered a major mechanism
of  EC  injury  [10-12].  Heparanase  is  a  mammalian
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1684endoglucuronidase responsible for HS degradation, and yields
HS  fragments  with  an  appreciable  size  (5–10  kDa)  and
biologic potency [10,13]. HS is a major constituent of the
ECM, and HS-degrading activity is thought to play a decisive
role in the fundamental biologic processes associated with
remodeling of the ECM, such as angiogenesis and cancer
metastasis. Heparanase activity has generally been shown to
correlate with cell invasion processes associated with cancer
metastasis,  which  is  a  consequence  of  a  structural
modification that loosens the ECM barrier [14-16].
Studies have suggested that heparanase may be induced
by hyperglycemia [17] and may contribute to EC dysfunction
by degrading HS. Adding heparanase to the media of cultured
endothelial  cells  results  in  injury  to  these  cells  [17].
Researchers  have  reported  that  heparanase  induction
correlates with increased tumor metastasis, vascular density,
and  a  shorter  post-operative  survival  rate,  thus  providing
strong  clinical  support  for  the  prometastatic  and
proangiogenic functions of this enzyme [18-21]. In addition
to the well studied catalytic characteristics of heparanase,
researchers have reported it exerts biologic functions that are
apparently independent of its enzymatic activity.
Recently, researchers reported that adding latent heparanase
stimulates  Akt-dependent  endothelial  cell  invasion  and
migration  activities  that  are  independent  of  heparanase’s
enzymatic  activity  [22].  Nonenzymatic  functions  of
heparanase  include  enhanced  adhesion  of  gliomas  [23],
lymphomas  [23,24],  and  T  cells  [25];  these  functions  are
mediated by β1-integrin and correlate with protein kinase B
(Akt), proline-rich tyrosine kinase 2 (Pyk2), and extracellular-
signal-regulated kinase (ERK) activation [23,25]. The ability
of heparanase to function in a nonenzymatic manner and to
elicit signal transduction cascades led us to hypothesize that
its potent angiogenic functions observed under clinical and
experimental settings are due to the release of HS–bound
growth factors and the regulation of human retinal vascular
endothelial cell (HREC) proliferation and migration. Thus,
our  objectives  were  to  determine  whether  heparanase  is
upregulated in HRECs exposed to high glucose and whether
heparanase  can  be  downregulated  using  a  specific  RNA
interference  (RNAi)  vector  in  HRECs  grown  under  high-
glucose  conditions.  Our  results  indicate  heparanase
expression  levels  correlate  with  HREC  proliferation  and
migration; furthermore, our data suggest the putative signal
transduction pathway by which this action occurs.
METHODS
Human retinal vascular endothelial cell culture and infection:
Our experiments followed the principles of the Declaration of
Helsinki. Cultured HRECs from the eyes of eight donors were
obtained from the Zhongshan Ophthalmic Center Eye Bank.
The donors, whose mean age was 22.3 years, were otherwise
healthy victims of accidents. To avoid significant pigment
epithelium contamination, we harvested the retinas carefully,
placed them in Hank’s balanced salt solution (137.93 mM
NaCl,  5.33  mM  KCl,  4.17  mM  NaHCO3,  0.441  mM
KH2PO4, 0.338 mM Na2HPO4, 5.56 mM D-Glucose), and
washed them. After we gently minced them, the retinal pieces
were digested in 2% trypsin for 20 min at room temperature,
collected by centrifugation at 217.3392× g, and resuspended
in 0.1% collagenase for 20 min at 37 °C. We centrifuged the
homogenate (150.93× g, 10 min), and resuspended the pellet
in  HE-SFM  supplemented  with  10%  fetal  bovine  serum
(FBS), 5 ng/ml recombinant human β-endothelial cell growth
factor (β-ECGF; R&D Systems, Minneapolis, MN), and 1%
insulin-transferrin-selenium.  We  cultured  the  cells  in
fibronectin-coated flasks and incubated them at 37 °C in a
humidified atmosphere containing 5% CO2. We characterized
the cultured cells for endothelial homogeneity by testing for
immunoreactivity  to  factor  VIII  antigen  using  light
microscopy. To avoid age-dependent cellular modification,
we used only cells at passages 2 and 3.
We purchased the Homo sapiens (human) heparanase
RNAi lentiviral expression vector (RNAi TargetSeq 5′-CCA
GGA  TAT  TTG  CAA  ATA  T-3′)  and  the  corresponding
control expression vector pGCSIL from Shanghai Genechem
Co. Ltd. (Shanghai, China). We seeded the lentivirus-infected
HRECs in six-well plates in HE-SFM media plus FBS, β-
endothelial cell growth factor (β-ECGF), and 1% insulin-
transferrin-selenium.  We  cultured  the  cells  in  fibronectin-
coated  flasks  and  incubated  at  37  °C  in  a  humidified
atmosphere containing 5% CO2 until the cells reached 40%
confluence. Subsequently, we added 3×106 TU per well of the
recombinant lentivirus to the cells and cultured them in an
incubator at 37 °C in 5% CO2 for three days at a multiplicity
of infection (MOI) of 60.
We used seven parallel wells for each group of HRECs:
untransfected HRECs were grown in HE-SFM in the presence
of 5 mM glucose medium supplemented with 30 mM mannitol
for  48  h  as  an  osmotic  control  (mannitol),  untransfected
HRECs were cultured in HE-SFM in the presence of either
5 mM (Glu5) or 30 mM glucose (Glu30) for 48 h, and control
pGCSIL-transfected HRECs (Con-LV) and lentivirus RNAi
heparanase-transfected HRECs (HPSE-LV) were cultured in
the presence of 30 mM glucose for 48 h (Con-LV-Glu30 and
HPSE-LV-Glu30,  respectively).  We  evaluated  the
phosphorylation levels of Akt and ERK using western blotting
and the level of heparanase expression using real-time reverse
transcription PCR and western blotting. We evaluated the
effects  on  cell  proliferation  using  3-(4,5-
dimethylthiahiazol-2-y1)-2,5-diphenyltetrazolium  bromide
(MTT) assays and bromodeoxyuridine (BrdU) staining, and
evaluated  the  effects  on  cell  migration  using  the  Boyden
chamber assay and paxillin immunofluorescent staining.
Quantification with quantitative real-time polymerase chain
reaction
After transfection, we extracted the total RNA from the
cells harvested from the different groups. We isolated the total
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determined the concentration and purity of the RNA samples
using a spectrophotometer. We purified the RNA from the
cells using Amplification Grade DNase I (AMPD1; Sigma-
Aldrich, St. Louis, MO), and used RNA reverse transcriptase
(PrimeScript RT Reagent Kit; DRR037A; TaKaRa, Tokyo,
Japan) to synthesize cDNA. We performed quantitative real-
time polymerase chain reaction (RT–PCR) assays using the
SYBR Green Real-Time PCR Master Mix (SYBR Premix Ex
Taq Kit, TaKaRa), and measured gene expression levels using
SYBR Green II (Qiagen, Tpkyo, Japan) and the ABI PRISM
7000 (Applied Biosystems Company, Foster City, CA) real-
time PCR system.
The PCR primers we used to detect heparanase and 18S
were as follows: heparanase sense strand (5′-CTC GAA GAA
AGA CGG CTA AGA-3′); heparanase reverse strand (5′-
TGG TAG CAG TCC GTC CAT T-3′); 18S sense strand (5′-
TTC CGA TAA CGA ACG AGA CTC T-3′); and 18S reverse
strand (5′-TGG CTG ACA CGC CAC TTG TC-3′).
Western blotting: We prepared cell lysates from the cells
grown  in  six-well  plates  (including  seven  sample  groups:
Glu5, mannitol, Glu30, Con-LV, HPSE-LV, Con-LV-Glu30,
and HPSE-LV-Glu30) by adding to each well 100 µl of lysis
buffer containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl,
0.5% Triton X-100, and a protease inhibitor cocktail (Sigma-
Aldrich,  Inc.).  We  centrifuged  the  harvested  samples  at
11,000× g at 4 °C for 30 min. We collected the supernatants,
and evaluated the protein supernatants using bicinchoninic
acid protein and assay kit (Bio-Rad, Hercules, CA). We mixed
lysates  containing  100  mg  of  protein  with  loading  buffer
containing 5% β-mercaptoethanol and heated them for 8 min
at 100 °C. We separated the samples with sodium dodecyl
sulfate–PAGE  and  subsequently  transferred  them  to
polyvinylidene  difluoride  membranes  (Bio-Rad).  We
incubated the membranes in blocking buffer (Tris-buffered
saline [TBS], 0.1% Tween-20, and 5% nonfat dry milk) for 1
h at room temperature, followed by hybridization with a rabbit
antiheparanase-1  polyclonal  antibody  (1:1,000  dilution;
Abcam,  Cambridge,  UK),  a  rabbit  antiphospho-Akt
monoclonal  antibody  (1:1,000  dilution;  Cell  Signaling
Technology,  Danvers,  MA),  a  rabbit  anti-Akt  (pan)
monoclonal  antibody  (1:1,000  dilution;  Cell  Signaling
Technology),  a  rabbit  antiphospho-ERK  monoclonal
antibody  (1:1,000  dilution;  Cell  Signaling  Technology),  a
rabbit anti-ERK (pan) monoclonal antibody (1:1,000 dilution;
Cell Signaling Technology), or a mouse antiactin monoclonal
antibody (1:1,000 dilution; Lab Vision, Fremont, CA) at 4 °C
overnight. After washing the membranes three times in TBS/
0.1%  Tween-20,  we  hybridized  the  membranes  with  a
horseradish  peroxidase-conjugated  antirabbit  or  antimouse
immunoglobulin G secondary antibody (1:1000 dilution; Cell
Signaling  Technology)  for  1  h  at  room  temperature.  We
washed the membranes three times in TBS/0.1% Tween-20,
and detected signals using chemiluminescence with luminol
(Santa Cruz Biotechnology, Santa Cruz, CA). We performed
semiquantitative analysis by measuring the optical densities
of the bands.
Cell migration assay: We performed a cell migration assay
using a specialized Boyden migration chamber that included
a  24-well  tissue  culture  plate  with  12  cell  culture  inserts
(Chemicon, Temecula, CA). The inserts contained an 8-µm
pore size polycarbonate membrane with a thin precoated layer
of  basement  membrane  matrix  (EC  Matrix).  Briefly,  we
starved HRECs, Con-LV, and HPSE-LV cells in 2% calf
serum overnight and then seeded them at a concentration of
5×103  cells/well  in  Transwell  plates.  We  added  culture
medium containing 10% FBS supplemented with either 5 mM
glucose (Glu5 group) or 30 mM glucose (Glu30, Con-LV-
Glu30, and HPSE-LV-Glu30 groups) to each upper chamber
and lower compartment. After 48 h of incubation at 37 °C, we
removed the HRECs from the upper surface of the membrane
using a moist cotton-tipped swab. We stained the migrating
cells  on  the  lower  surface  of  the  membrane,  which  had
migrated through the polycarbonate membrane, with crystal
violet staining solution for 30 min and rinsed them three times
with distilled water. We quantified migration by selecting 10
different views repeated 400 times and calculating the number
of migrating cells.
Cell proliferation assay: We used an MTT assay to quantify
cell proliferation. We initially grew HRECs to confluence
before  seeding  them  into  a  96-well  plate  at  a  density  of
4×103 cells/well for 48 h. We determined cell viability by
adding 200 µl of 5 mg/ml MTT assay to each well followed
by  incubation  for  an  additional  4  h.  We  solubilized
precipitates by adding 150 µl of dimethyl sulfoxide (DMSO)
to  each  well.  After  10  min  of  shaking,  we  assessed  the
absorbance value (A value) at 570 nm. The observed optical
density directly correlated to the number of cells. We repeated
these experiments three times.
Immunofluorescent  staining:  For  immunofluorescent
staining, we fixed the cells with 4% paraformaldehyde for 20
min,  washed  them  with  phosphate  buffer  solution  (PBS,
KH2PO4 0.27 g,Na2HPO4 1.42 g, NaCl 8 g, KCl 0.2 g, and add
the whole liquid is 1000 ml, pH is 7.4), and permeabilized
them with 0.5% Triton X-100 in PBS for 15 min. We then
incubated the cells in PBS containing 10% normal goat serum
for 1 h at room temperature, followed by 1 h of incubation
with  the  indicated  primary  antibody  (rabbit  antipaxillin
monoclonal  antibody;  1:250  dilution;  Abcam).  We
thoroughly washed the cells with PBS and incubated them
with  the  appropriate  Cy3-conjugated  secondary  antibody
(1:250 dilution; Jackson ImmunoResearch, West Grove, PA)
for 1 h. Then we washed the cells with PBS, stained them with
Hoechst 33342 (Sigma-Aldrich) for 5 min, washed them with
PBS again, and mounted them. We observed staining under a
fluorescence microscope.
To assess cell growth using bromodeoxyuridine (BrdU)
staining, we counted the cells every day for four days after
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numbers by counting with a hemocytometer. Additionally, we
analyzed cell proliferation by measuring BrdU (10 μmol/l;
Sigma-Aldrich)  incorporation  using  a  cell  proliferation
labeling  reagent.  Briefly,  we  incubated  subconfluent  cells
grown  on  glass  coverslips  in  complete  growth  medium
supplemented  with  5  or  30  mM  glucose  for  48  h  in  the
presence of BrdU, fixed them with 4% paraformaldehyde for
20 min, permeabilized them with 1.0% Triton X-100 in PBS
for 15 min, washed them with PBS, and incubated them with
PBS containing 10% normal goat serum for 1 h at room
temperature. We then incubated the cells with a mouse anti-
BrdU  antibody  (1:20  dilution;  Abcam)  for  1  h  at  room
temperature,  thoroughly  washed  them  with  PBS,  and
incubated  them  with  the  appropriate  Cy3-conjugated
secondary  antibody  (1:250  dilution;  Jackson
ImmunoResearch)  for  1  h  at  room  temperature.  We
subsequently  washed  and  stained  the  cells  with  Hoechst
33342 (Sigma-Aldrich) for 5 min, washed with them PBS, and
mounted them. We observed staining under a fluorescence
microscope. We determined the mitotic index by calculating
the number of BrdU-positive nuclei as a percentage of the total
number of cells.
Statistical analysis: Data are presented as the mean±SD. We
analyzed statistical significance with one-way ANOVA using
the  GraphPad  Prism  4.0  software  system  (GraphPad,  San
Diego, CA) and the statistical software program SPSS 16.0
for  Windows  (Chicago,  IL).  Values  of  p<0.05  were
considered significant in all cases.
RESULTS
Heparanase expression increased in human retinal vascular
endothelial  cells  under  high-glucose  conditions:  HREC
cultures were established successfully, and the percentage of
factor VIII-positive cells in the cultured cells was 96.7%. We
conducted in vitro cell culture studies to determine whether
heparanase expression was upregulated in HRECs under high-
glucose  conditions.  As  shown  in  Figure  1,  heparanase
expression was significantly higher (2.6 fold) in high-glucose-
treated HRECs than in HRECs grown in normal medium
(p<0.01). HRECs grown in normal medium supplemented
with 30 mM mannitol (as an osmotic control) showed no
Figure  1.  Heparanase  expression  in
human retinal vascular endothelial cells
under high-glucose conditions for 48 h
is  increased  than  in  the  Glu5  and
mannitol control groups. A, B: We used
western blotting to determine that the
expression  of  heparanase  in  human
retinal  vascular  endothelial  cells
(HRECs)  grown  in  conditioned
medium.  The  band  that  represents
heparanase expression was more intense
in the Glu30 group than in the Glu5 and
mannitol  control  groups.  Each  group
experiment was repeated 3 times (n=3).
*  compared  with  the  Glu30  group
(p<0.01); ** compared with the Glu5
and mannitol control groups (p<0.01).
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1687change  in  heparanase  protein  levels  compared  with  cells
grown in normal medium.
Expression  of  heparanase  in  human  retinal  vascular
endothelial  cells  is  suppressed  by  RNA  interference:  To
determine the effects of the transfection of heparanase RNAi
on the expression of HREC heparanase, we observed green
fluorescent protein expression under fluorescence microscopy
in HRECs 72 h after infection with HPSE-RNAi-LV. We
performed real-time PCR and western blotting to determine
the mRNA and protein levels of heparanase in the HPSE-LV
and  Con-LV  groups  and  HRECs.  These  analyses
demonstrated  that  HPSE-LV  significantly  inhibited  the
expression  of  heparanase  mRNA  (p=0.006,  p=0.007)  and
protein compared with uninfected HRECs and the Con-LV
group (Figure 2).
Heparanase expression in human retinal vascular endothelial
cells: To determine the effects of heparanase RNAi treatment
on the expression of heparanase mRNA and protein in high-
glucose-treated HRECs, we performed real-time PCR and
western blotting analysis on samples from the Glu5, Glu30,
Con-LV-Glu30,  and  HPSE-LV-Glu30  groups.  Heparanase
RNAi  significantly  reduced  the  expression  of  heparanase
mRNA (p=0.004, Figure 3C) and protein (p<0.001, Figure
3A,B)  in  high-glucose-treated  HRECs  compared  with  the
Glu30  and  Con-LV-Glu30  groups.  Heparanase  mRNA
(p<0.001, Figure 3C) and protein (p<0.001, Figure 3A,B)
expression in Glu30 cells was significantly higher than in the
Glu5  and  HPSE-LV-Glu30  groups.  Therefore,  the
heparanase-specific RNAi treatments used in our study are
efficient  at  downregulating  the  increased  expression  of
heparanase  in  high-glucose-treated  HRECs.  We  next
examined  whether  heparanase  levels  correlate  with  the
proliferation and migration of HRECs.
Effects  of  heparanase  expression  levels  on  human  retinal
vascular endothelial cell proliferation: To determine whether
heparanase expression levels correlate with the proliferation
of HRECs, we examined the effects of the high-glucose and
RNAi treatments on HREC growth using MTT and BrdU
assays. We found that the growth of cells infected with HPSE-
LV  was  markedly  inhibited  compared  with  the  Con-LV-
Glu30 and Glu30 groups. However, the growth of cells in the
Glu30 group was significantly higher than in the HPSE-LV-
Glu30 and Glu5 groups (p<0.001, Figure 4A-C). These results
show  that  heparanase  overexpression  due  to  high-glucose
conditions correlates with HREC proliferation. Furthermore,
our results demonstrate that the RNAi method used in our
study  to  knock  down  high-glucose-induced  heparanase
expression  is  also  efficient  at  inhibiting  increased  HREC
proliferation.
Effects  of  heparanase  expression  levels  on  human  retinal
vascular  endothelial  cells’  migration  ability:  To  evaluate
whether  heparanase  expression  levels  correlate  with  the
migration of HRECs, we performed an in vitro cell migration
assay using paxillin, and determined the number of cells that
migrate  across  Boyden  chambers.  Heparanase  RNAi
markedly reduced the number of cells that migrated through
the chamber compared with the Con-LV-Glu30 (p<0.001) and
the Glu30 groups, while the Glu30 group’s migration ability
was significantly higher than the HPSE-LV-Glu30 and Glu5
groups (p<0.001, Figure 5A,C).
Figure 2. Expression of heparanase in
human retinal vascular endothelial cells
is  suppressed  by  RNAi.  A:  Human
retinal  vascular  endothelial  cells
(HRECs) were infected with Con-LV or
heparanase  small  interfering  RNA
recombinant  lentiviral  vector  (HPSE-
LV) at a multiplicity of infection (MOI)
of 60. Green fluorescent protein (GFP)
expression  and  phase  contrast  images
were  captured  after  72  h  (original
magnification  ×  200).  B:  The
heparanase mRNA levels were detected
using real-time PCR after the HRECs
were treated with HPSE-LV and Con-
LV.  HPSE-LV  significantly  inhibited
the  expression  of  HREC  heparanase
mRNA  (●p<0.01,  compared  with
HRECs; ▲p<0.01, compared with the
Con-LV group). Each group experiment
was repeated 3 times (n=3). C: western
blotting  analysis  showed  that  the
heparanase  protein  was  markedly
inhibited by HPSE-LV in HRECs.
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1688Paxillin acts as an adaptor protein that localizes to focal
adhesions during cell migration. Immunofluorescent staining
showed that in the Glu30 and Con-LV-Glu30 groups, paxillin
expression in the HRECs was significantly higher than in the
HPSE-LV-Glu30 and Glu5 groups (Figure 5B). However, in
the  HPSE-LV-Glu30  group,  paxillin  expression  was
markedly reduced compared with the Con-LV-Glu30 (Figure
5B) and Glu30 groups.
Enhanced cell proliferation by heparanase is mediated by Akt
and extracellular-signal-regulated kinase: To pinpoint the
signal  transduction  pathway  by  which  the  effects  of
heparanase-induced  endothelial  cell  proliferation  and
migration may occur, we analyzed the levels of ERK and Akt
phosphorylation using western blotting. We noted significant
activation of Akt and ERK phosphorylation in the Glu30
group cells stimulated by heparanase overexpression, while
Akt and ERK activation was abolished in the HPSE-LV-
Glu30  group  (p<0.001,  Figure  6  A,B).  Additionally,  cell
proliferation stimulated by heparanase overexpression in the
Glu30 group was significantly increased, but in the HPSE-
LV-Glu30  group,  cell  proliferation  was  inhibited.  Taken
together,  these  results  indicate  that  Akt  and  ERK
phosphorylation  and  activation  due  to  heparanase
overexpression correlate with increased cell proliferation and
migration.
DISCUSSION
In  addition  to  the  traditional  enzymatic  function  of  ECM
degradation, heparanase facilitates the adhesion, spreading,
Figure  3.  Expression  of  heparanase
protein  and  mRNA  in  high-glucose-
treated  human  retinal  vascular
endothelial cells is suppressed by RNAi.
A, B: HPSE-LV significantly inhibited
human retinal vascular endothelial cells
(HRECs) heparanase protein expression
in the heparanase small interfering RNA
recombinant  lentiviral  vector  (HPSE-
LV)-Glu30  group  compared  with
HRECs  in  the  Glu30  and  Con-LV-
Glu30  groups  (●p<0.01  versus  Glu5;
▲p<0.01  versus  HPSE-LV-Glu30
group).  Each  group  experiment  was
repeated  3  times  (n=3).  C:  Real-time
PCR analysis showed that heparanase
mRNA was markedly inhibited in the
HPSE-LV-Glu30 group compared with
HRECs  in  the  Glu30  and  Con-LV-
Glu30  groups  (●p<0.01  versus  Glu5;
▲p<0.01  versus  HPSE-LV-Glu30).
Each group experiment was repeated 3
times (n=3).
Molecular Vision 2012; 18:1684-1695 <http://www.molvis.org/molvis/v18/a173> © 2012 Molecular Vision
1689and migration of several cell types in a manner that appears
to  be  independent  of  its  enzymatic  activity  [22,23,25].
Researchers have previously reported that the nonenzymatic
functions  of  heparanase  include  enhanced  adhesion  of
gliomas [23], lymphomas [23,24], and T cells [25]; these
functions are mediated by β1-integrin and correlate with Akt,
Pyk2, and ERK activation [23,25]. Increased expression of
heparanase mRNA and protein in tumors is evident in tissue
specimens  derived  from  adenocarcinomas  of  the  ovary,
metastatic  melanomas,  oral  squamous  cell  carcinomas,
hepatocellular carcinomas, and carcinomas of the prostate,
bladder,  and  pancreas  [26-35].  Studies  have  reported  that
inhibiting the expression of heparanase can impede tumor
invasion, metastasis, and angiogenesis; therefore, heparanase
is a critical cancer target [30,36].
Heparanase is also an important vasculopathy target. In
diabetes, the ECs lining all vessels appear to be the initial
target of vascular damage due to hyperglycemia. Previous
studies have shown that heparanase mRNA and activity were
detected in ECs treated with high glucose and H2O2, which
cause EC injury. An increase in osmolarity is not likely the
cause of heparanase upregulation because heparanase mRNA
and activity was not found in mannitol-treated cells [37]. ECs
in  the  macrovessels  and  microvessels  have  different
Figure 4. We used 3-(4,5-dimethylthiahiazol-2-y1)-2,5-diphenyltetrazolium bromide and bromodeoxyuridine staining assays to determine
that  effects  of  heparanase  expression  on  human  retinal  vascular  endothelial  cell  proliferation.  A:  3-(4,5-dimethylthiahiazol-2-y1)-2,5-
diphenyltetrazolium bromide (MTT) assays revealed that cell proliferation in the heparanase small interfering RNA recombinant lentiviral
vector (HPSE-LV)-Glu30 group was significantly suppressed by HPSE-LV compared with the Con-LV-Glu30 and Glu30 groups. Human
retinal vascular endothelial cell (HREC) proliferation in the Glu30 group was significantly higher than in the Glu5 and HPSE-LV-Glu30
groups  (●p<0.01  versus  Glu5;  ▲p<0.01  versus  HPSE-LV-Glu30).  Each  group  experiment  was  repeated  3  times  (n=3).  B,  C:
Bromodeoxyuridine (BrdU) staining assays revealed that HPSE-LV-Glu30 cell growth was significantly lower than in the Con-LV-Glu30
and Glu30 groups. The HREC growth of the Glu30 group was significantly higher than in the Glu5 and HPSE-LV-Glu30 groups. (●p<0.01
versus Glu5; ▲p<0.01 versus HPSE-LV-Glu30). Data are presented as the mean±SD. Each group experiment was repeated 3 times (n=3).
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1690properties, but both are characterized by the same pathological
features in patients with diabetes mellitus, such as exaggerated
proliferation  of  ECs  and  thickening  of  the  basement
membrane.  This  proliferation  and  thickening  result  in  the
narrowing of the vessel lumen, which contributes to premature
thrombosis  and  ischemia,  leading  to  vascular  remodeling
[38,39].
To  determine  the  effects  of  heparanase  on  HREC
proliferation  and  migration,  we  used  a  heparanase  RNAi
lentiviral vector to deplete heparanase expression (Figure 2).
Our results show that while the heparanase gene was highly
expressed in high-glucose-treated HRECs (the Glu30 group,
Figure  3),  RNAi  effectively  inhibited  heparanase  gene
expression in high-glucose-treated HRECs (the HPSE-LV-
Glu30 group; Figure 3). Heparanase gene expression did not
Figure 5. We used Boyden chambers and paxillin immunofluorescence staining assays to determine that effects of heparanase expression
levels on human retinal vascular endothelial cell migration. A: The human retinal vascular endothelial cells (HRECs) that are stained with
crystal violet are those that migrated across the extracellular matrix (ECM) in the specialized migration chamber by migrating through the
polycarbonate membrane to the lower surface of the membrane (original magnification 200×). B: Paxillin immunofluorescence staining
indicated positive paxillin protein expression in every group. HPSE-LV significantly inhibited HREC paxillin protein expression compared
with the Con-LV-Glu30 and Glu30 groups. The paxillin protein expression in the Glu30 group was significantly higher than in the HPSE-
LV-Glu30 and Glu5 groups (the yellow arrow indicates paxillin). C: Heparanase small interfering RNA recombinant lentiviral vector (HPSE-
LV) significantly decreased the HRECs’ migration ability. Bars indicate the mean±SD (p<0.05). The HPSE-LV-Glu30 group showed a
markedly decreased migration ability compared to the Con-LV-Glu30 (p<0.01) and Glu30 groups, which migrated significantly more than
the HPSE-LV-Glu30 and Glu5 groups (●p<0.01 versus Glu5; ▲p<0.01 versus HPSE-LV-Glu30). Each group experiment was repeated 3
times (n=3).
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1691change in the 30 mM mannitol-treated HRECs (the mannitol
group, Figure 2). Moreover, the proliferation and migration
of HPSE-LV-infected cells were lower than those of the Con-
LV-Glu30 and Glu30 groups (Figure 4 and Figure 5). Our
results show that in the Glu30 and Con-LV-Glu30 groups,
HREC paxillin expression is significantly higher than in the
Figure 6. Effects of heparanase expression levels on human retinal vascular endothelial cell AKT and extracellular signal regulated kinase
(ERK) protein expression western blotting analyses showed that the levels of phosphorylated ERK and Akt were enhanced by heparanase
overexpression. A, B: HPSE-LV-Glu30 human retinal vascular endothelial cells (HRECs) showed significantly reduced ERK and Akt
phosphorylation levels compared with the Con-LV-Glu30 and Glu30 groups. The ERK and Akt phosphorylation levels of the Glu30 HRECs
were significantly higher than the HPSE-LV-Glu30 and Glu5 groups. (●p<0.01 versus Glu5 p-Akt; ▲p<0.01 versus HPSE-LV-Glu30 p-Akt;
★p<0.01 versus Glu5 p-ERK; ■p<0.01 versus HPSE-LV-Glu30 p-ERK). Bars indicate the mean±SD, p<0.05. Each group experiment was
repeated 3 times (n=3).
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1692HPSE-LV-Glu30 and Glu5 groups (Figure 5B). Paxillin acts
as an adaptor protein that localizes to focal adhesions and is
regulated during cell migration via phosphorylation of its
tyrosine,  serine,  and  threonine  residues.  Most  of  these
phosphorylation sites have been implicated in regulating the
different steps of cell migration.
The  results  of  the  present  study  show  that  decreased
heparanase  expression  inhibits  HREC  proliferation  and
migration. Importantly, HREC proliferation and migration
may  contribute  to  increased  angiogenesis  in  established
diabetic retinopathy. Therefore, there is a strong relationship
between  heparanase  levels  and  HREC  migration  and
proliferation. The present work also revealed a relationship
between HREC heparanase expression levels and Akt and
ERK phosphorylation levels; the observed upregulation or
downregulation  of  heparanase  expression  enhanced  or
inhibited ERK and Akt phosphorylation, respectively, thereby
mediating  HREC  proliferation  and  migration  (Figure  6).
Importantly, this result further supports the hypothesis that in
correlation  with  ERK-  and  Akt-dependent  HREC
proliferation  and  migration,  heparanase  overexpression
accelerates the angiogenic processes. Activation of the ERK
and Akt pathways plays a major role in regulating cell growth,
proliferation, differentiation, and angiogenesis and provides
a protective effect against apoptosis and vascular remodeling
[40,41].
Heparanase  upregulation  might  also  be  common  in
injured  ECs  from  large  and  small  vessels.  Heparanase
activates endothelial cells and elicits angiogenic responses.
Adding the 65-kDa latent heparanase protein to endothelial
cells enhances Akt and ERK signaling. Heparanase-mediated
Akt and ERK phosphorylation is independent of heparanase
enzymatic activity and of the presence of cell membrane HS
proteoglycans.  Heparanase  also  stimulates
phosphatidylinositol  3-kinase-dependent  endothelial  cell
migration and invasion [22].
In conclusion, numerous ocular diseases result in the
growth of new blood vessels within the eye. Diabetic vascular
complications are primarily caused by injury to ECs. ECs play
a pivotal role in regulating vascular tone, and injury of these
cells  is  the  initial  step  leading  to  irreversible  structural
abnormalities.  Furthermore,  HREC  proliferation  and
migration  may  contribute  to  increased  angiogenesis  in
established diabetic retinopathy. Our results reveal that high
glucose  levels  induced  the  upregulation  of  heparanase
expression in HRECs. This study further demonstrated that
upregulation  or  downregulation  of  heparanase  expression
enhanced  or  inhibited  ERK  and  Akt  phosphorylation,
respectively; these changes in ERK and Akt phosphorylation
correlate with changes in HREC proliferation and migration.
Therefore, these findings provide the basis for further studies
focusing  on  understanding  and  treating  diabetic  vascular
complications.
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